AACR 2020: New therapy with potential benefit for underserved patients with lung and ovarian cancers
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1),…
Browsing: IPN60090
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- The OJC Episode 23: ASCO GI Special
- Human pancreatic cancer model offers new opportunities for testing drugs
- Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
- Poor brain cancer survival outcomes on the rise
- Oesophageal cancer: 3-D printed stents deliver breakthrough treatment
- Potential therapeutic targets to inhibit colorectal cancer progression
- UK Lockdowns: Significant reduction in new cancer diagnoses
- More than half of cancer survivors have underlying medical conditions associated with severe COVID
